5 years ago

Pneumagen Secures GBP2.5M for Respiratory Infection Treatments

  • Pneumagen, a UK-based company focused on preventing and treating respiratory infections, has raised GBP2.5m in funding

  • The investment will be used to support the clinical development of Neumifil™ in 2021 as an intra-nasal formulation for the prevention and treatment of influenza, Respiratory Syncytial Virus (RSV) and COVID-19

  • The funding was provided by existing investors and a new undisclosed global corporate investor.

      • ProblemHealthcare

      "preventing and treating respiratory infections"

      Solution

      "developing glycan targeted carbohydrate-binding module domains (mCBMs) for prophylaxis and treatment of respiratory tract infections"

      Covered on